ERC-Belgium S. A. Their main focus is on treating patients with Glioblastoma multiforme (GBM), the deadliest form of brain cancer, through their patented Gliovac/ERC1671 vaccine.

With a dedicated team of experts in the field, including Founder & CEO Apostolos Stathopoulos, MD, PhD, and Chief Scientific Officer Virgil Schijns, PhD, ERC is at the forefront of immunotherapy research and development. They offer a range of products and services, including clinical trials, right to try options, and product manufacturing. Their goal is to provide innovative solutions to cancer treatment and improve patient outcomes.

With their extensive experience and commitment to advancing cancer therapies, ERC-Belgium S. A